Five trials, three compounds and short follow-up
Selective orexin receptor type 2 agonists, or OX2R agonists, target the orexin deficiency underlying type 1 narcolepsy. This approach now has clinical results beyond its mechanistic rationale.
The review brings together five randomized, double-blind, placebo-controlled trials evaluating oral treatments: TAK-994, oveporexton or alixorexton. They included a total of 550 participants, followed for 6 to 12 weeks. However, the main efficacy synthesis covers 337 participants, not everyone who was randomized.
Measured improvements, with varying certainty
Compared with placebo, the treatments increased the time before falling asleep on the Maintenance of Wakefulness Test by an average of 22.7 minutes. The 95% confidence interval ranges from 16.8 to 28.7 minutes. This is a test result, not extra minutes of sleep at night. The certainty of this estimate is rated as low, notably because of substantial differences between trials.
The Epworth Sleepiness Scale score decreased by an average of 9.8 points compared with placebo. The weekly cataplexy rate fell by 69% in relative terms. The abstract does not provide the absolute rates needed to translate this reduction into the number of episodes prevented. The certainty of the evidence is rated as moderate for both outcomes.
Tolerability prevents a class-wide conclusion
Frequent urination, urinary urgency, insomnia and excessive salivation were more common with treatment. The TAK-994 program was stopped following liver toxicity. This signal concerns that compound and is not enough to attribute the same risk to all OX2R agonists.
Conversely, a few weeks of follow-up cannot establish the long-term safety of the other compounds. These findings concern type 1 narcolepsy: they do not demonstrate any benefit in people without this condition.
Limitations to keep in mind
This analysis is based solely on the supplied PubMed abstract, without consulting the full text. The number of trials is limited, follow-up lasts 6 to 12 weeks, and Maintenance of Wakefulness Test results are heterogeneous. Funding and conflicts of interest have not been verified.
What we can take away
These trials support a short-term benefit of OX2R agonists in type 1 narcolepsy. They do not yet establish the long-term safety of the entire class.
Sources and provenance
- Efficacy and safety of selective orexin 2 receptor agonists in narcolepsy type 1: a systematic review and meta-analysis of randomized controlled trials.
Source date: 2026-11-11.
Journal Article, Systematic Review, Meta-Analysis, Review · Résumé PubMed uniquement, texte intégral non consulté


